The investment of Momenta Pharmaceuticals, Insmed and Cell Therapeutics in technology to develop duplicates of biotech drugs may pay off if Congress allows the sale of follow-on biologics in the U.S. Momenta is working with Novartis AG's Sandoz unit to make a version of Lovenox, Sanofi-Aventis SA's blood thinner, and three other biotech medicines. Cell Therapeutics is working on a technology to simplify production of gene-based drugs, while Insmed will begin human trials of two follow-on biotech treatments this year.

Full Story:

Related Summaries